Elaine Sorg

Director

Elaine Sorg is a highly accomplished biopharmaceutical executive with more than 35 years of experience leading large, complex organizations and building category-defining immunology franchises, with particular depth in rheumatoid arthritis and other immune-mediated diseases. As Vice President, U.S. Immunology at AbbVie, she led the HUMIRA® franchise, and later as President, U.S. Immunology and AbbVie Patient Services, she drove the strategy, launch, and expansion of leading therapies including HUMIRA®, SKYRIZI®, and RINVOQ® across indications such as rheumatoid arthritis, plaque psoriasis, and Crohn’s disease. Her leadership helped establish and extend standards of care in immunology while building high-performing, cross-functional commercial and medical teams centered on patient impact. Ms. Sorg most recently served as Senior Vice President, AbbVie and President, U.S. Commercial Operations. In that role, she oversaw multibillion-dollar brands and guided the business through significant market transitions, including the loss of exclusivity for HUMIRA, while positioning next-generation immunology therapies for sustained growth. Prior to AbbVie, she spent 23 years at Eli Lilly and Company in senior sales, marketing, engineering, and general management roles, including as Cymbalta Brand Leader, where she led successful indication expansion and commercialization efforts. Ms. Sorg currently serves as a Senior Advisor to the Boston Consulting Group and is a member of the Board of Directors of CSL Limited, where she contributes to the Innovation and Development Committee and the Human Resources and Remuneration Committee, and she also serves on the Scientific Advisory Board for Galapagos.